What is Eli Lilly's D&A?

Eli Lilly (LLY) reported D&A of $509M in Q1 2026.

How has Eli Lilly's D&A changed year-over-year?

Eli Lilly's D&A increased by 9.9% year-over-year, from $463M to $509M.

What is the long-term trend for Eli Lilly's D&A?

Over 4 years (2021 to 2025), Eli Lilly's D&A has grown at a 6.6% compound annual growth rate (CAGR), from $1.55B to $2B.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Eli Lilly LLY D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

AmgenAMGN

$1.12B-19.5%

Cardinal HealthCAH

$248M+19.8%

MannkindMNKD

$6.38M+203%

Oruka Therapeutics, Inc.ORKA

$43K+169%

McKessonMCK

$65M+12.1%

Other financials

Income statement

See full

Revenue$19.8B+55.5%

Gross profit$16.2B+54.4%

Net income$7.4B+168%

EPS (diluted)$8.26+170%

Balance sheet

See full

Cash & equivalents$5.3B+70.8%

Total debt$43.4B+12.6%

Total equity$31.2B+97.9%

Total assets$116.58B+30.4%

Cash flow

See full

Operating cash flow$5.3B+220%

CapEx$2.3B+54.0%

Free cash flow$3.0B+1,828%

Valuation

See full

Market cap$1.08T+54.2%

Enterprise value$1.12T+51.7%

P/E42.6×-8.0×

P/S14.9×+1.8×

Profitability

See full

Gross margin82.8%+1.1pp

Net margin35%+12.3pp

FCF margin16.4%+8.7pp

Returns & leverage

See full

Return on equity107.6%+29.9pp

Debt / equity1.4×-1.1×

Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eli Lilly's D&A?: Eli Lilly (LLY) reported D&A of $509M in Q1 2026.
How has Eli Lilly's D&A changed year-over-year?: Eli Lilly's D&A increased by 9.9% year-over-year, from $463M to $509M.
What is the long-term trend for Eli Lilly's D&A?: Over 4 years (2021 to 2025), Eli Lilly's D&A has grown at a 6.6% compound annual growth rate (CAGR), from $1.55B to $2B.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.